TRAX

First Tracks Biotherapeutics Inc

• TipRanks·07/10 13:15

  First Tracks Biotherapeutics Inc (TRAX) Gets a Buy from UBS

• TipRanks·07/10 11:15

  J.P. Morgan Remains a Buy on First Tracks Biotherapeutics Inc (TRAX)

• Dow Jones·07/10 10:23

  First Tracks Price Target Raised to $44.00/Share From $30.00 by HC Wainwright & Co.

• Dow Jones·07/10 10:23

  First Tracks Is Maintained at Buy by HC Wainwright & Co.

• Benzinga·07/10 10:13

  HC Wainwright & Co. Maintains Buy on First Tracks, Raises Price Target to $44

• TipRanks·07/10 10:05

  First Tracks Biotherapeutics price target raised to $44 from $30 at H.C. Wainwright

• Reuters·07/10 10:04

  FIRST TRACKS BIOTHERAPEUTICS, INC. <TRAX.O>: H.C. WAINWRIGHT RAISES TARGET PRICE TO $44 FROM $30

• TipRanks·07/10 09:55

  Wells Fargo Reaffirms Their Buy Rating on First Tracks Biotherapeutics Inc (TRAX)

• TipRanks·07/10 08:11

  Analysts Offer Insights on NA Companies: Fervo Energy Company Class A (FRVO) and First Tracks Biotherapeutics Inc (TRAX)

• NASDAQ·07/10 02:50

  Top Biotech Gainers: VRAX Jumps 100% After Fosun Deal, FBRX Soars On Vitiligo Data, TRAX On Watch

• Benzinga·07/09 17:05

  12 Health Care Stocks Moving In Thursday's Intraday Session

• Benzinga·07/09 14:01

  Aehr Test Systems, Lam Research, Applied Materials And Other Big Stocks Moving Higher On Thursday

• Dow Jones·07/08 13:48

  First Tracks Price Target Maintained With a $30.00/Share by HC Wainwright & Co.

• Benzinga·07/08 13:44

  HC Wainwright & Co. Reiterates Buy on First Tracks, Maintains $30 Price Target

• TipRanks·07/08 13:25

  Buy Rating on First Tracks (TRAX) Driven by Strengthening IL-15/CD122 Pathway Validation and Upcoming ANB033 Clinical Catalysts in Celiac Disease and Vitiligo